CompanyOTCCharlotte, NC
Adaptin Bio, INC
Adaptin Bio develops APTN-101, a brain bispecific T cell engager targeting EGFRvIII-expressing gliomas.
424B3Sep 10Latest SEC filing
Form DJun 22$1.9M sold
Sign inSign inAdaptin Bio develops APTN-101, a brain bispecific T cell engager targeting EGFRvIII-expressing gliomas.